A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

This Study is
No Longer Enrolling

Details
Age

Adult

Phase

III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 19-0820

More information available at ClinicalTrials.gov: NCT03383458

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers